Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10085396			
iling Date		2002-02-28			
First Named Inventor Walla		ice			
Art Unit		2121			
Examiner Name	Hartman				
Mornoy Docket Number		D4965-00004			

				Attorney Doc	xer number	D4003-00004			
				U.S.	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>			Releva	Columns,Lines wher int Passages or Rele s Appear	e van	
	1	4788648	B2	1988-11-29	Ferretti				
	2	5533648	B2	1996-07-09	Read				
If you wisl	h to a	dd additional U.S. Pate	nt citatio	n information p	lease click the	Add button.	_	Add	
			U.S.P	ATENT APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Publication Name of Patentee or Applicant		Releva	Columns,Lines wher int Passages or Rele s Appear	
	1	dd additional U.S. Publ						Add	
ii you wisi	n to ac	da additional O.S. Publ		FORFIGN PA			a bullon	Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	y Kind		Name of Patente Applicant of cited Document	e or	ages,Columns,Lines where Relevant Passages or Relevan igures Appear	1
	1						Ī		[
If you wis	h to a	dd additional Foreign P					button	Add	_
				I-PATENT LITI				Remove	

	Application Number		10085396	
NEODWATION DIGGI COURT	Filing Date		2002-02-28	
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Wallace		
Not for submission under 37 CFR 1.99)	Art Unit		2121	
and of one many	Examiner Name Hartn		nan	
	Attorney Docket Number		D4865-00004	

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5	
	1			

If you wish to add additional non-patent literature document citation information please click the Add button Add

FXAMINER SIGNATURE

Examiner Signature | Date Considered |

EXAMINER: nitial if reference considered, whether or not citation is in conformance with MIPED. Draw line through a citation in fine conformance and not considered, include copy of this form with next communication to applicant.

See Kint Code of USPTO Patent Documents at year USPTO\_GOV or NEPP 901.04. Enter office that issued the document, by the to-recode (NPD Standard ST.3) "For duplence patent coder (NPD columents), the solicition of the year of the region of the Emperor than procedure the section of the USPTO Standard ST.3 "Standard ST.3" Applicant is to place a check mark there if Employed Standard ST.16 if possible. "Applicant is to place a check mark there if Employed Standard ST.16 if possible." Applicant is to place a check mark there if Employed Standard ST.16 if possible. "Applicant is to place a check mark there if Employed Standard ST.16 if possible."

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10085396		
Filing Date		2002-02-28		
First Named Inventor	Wallace			
Art Unit		2121		
Examiner Name	Hartman			
Attorney Docket Number		D4865-00004		

#### CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to	make the	appropriate s	election(s):
---------------	----------	-------------	----------	---------------	--------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sec 37 CFR 197(eVI).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to [2] any individual designated in 37 CFR 1.58(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.59(c) The 1.58(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Samuel W. Apicelli/	Date (YYYY-MM-DD)	2006-10-09
Name/Drint	Comunity Anigotti	Registration Number	36 427

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolline is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient of the patient application or patient. If you do not furnish the requested related to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may related that the patient process and/or examine your submission.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application port to public insepticines or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.